BEONE MEDICINES (06160): The new subscription period for the 2018 Employee Stock Ownership Plan will start from March 2nd and end on August 31st.
Baiji Shenzhou (06160) announced that a new round of employee stock purchase plan subscription period will take place from March 2, 2026 to August 31, 2026. Eligible employees will purchase shares (including in the form of American Depositary Shares) after the subscription period ends, with the purchase funds deducted from their earnings during the subscription period.
BEONE MEDICINES (06160) announced that the new round of employee share purchase plan for 2018 will be open for subscription from March 2, 2026, to August 31, 2026. Eligible employees will be able to purchase shares (including in the form of American depositary shares) using funds deducted from their earnings during the subscription period.
The 2018 employee share purchase plan allows eligible employees to purchase shares at a 15% discount off the market price (including in the form of American depositary shares). Employees can use funds deducted from their earnings during the subscription period to purchase shares after the subscription period ends. The 2018 employee share purchase plan is managed by the board's remuneration committee.
The company believes that providing opportunities for employees to participate in the 2018 employee share purchase plan and gain ownership rights in the company will encourage them to continue their employment with the company and align their interests more closely with those of the company's shareholders, in line with the best interests of the company and its shareholders.
Related Articles

On March 9th, PRU(02378) spent 3.9421 million pounds to repurchase 375,400 shares.

HIGHTIDE-B(02511): New drug application for HTD1801 has been accepted by the China National Medical Products Administration.

Volkswagen's profits plunged 45%: Costs and competition squeezing margins, limited profit recovery this year.
On March 9th, PRU(02378) spent 3.9421 million pounds to repurchase 375,400 shares.

HIGHTIDE-B(02511): New drug application for HTD1801 has been accepted by the China National Medical Products Administration.

Volkswagen's profits plunged 45%: Costs and competition squeezing margins, limited profit recovery this year.

RECOMMEND

Local Policies Experiment With “Lobster” AI Agents Accelerate Into The Agent Era But Security Risks Remain
10/03/2026

Hong Kong And Macau Join Billion‑Level Guidance Fund Initiative Hong Kong Sets Return‑Investment KPI Macau Targets MOP 20 Billion
10/03/2026

Southbound Capital Sells Heavily Yet Hang Seng Tech Advances How Do Fund Managers Interpret It
10/03/2026


